Cargando…

The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study

BACKGROUND: Patients on therapeutic immunosuppressants for immune-mediated inflammatory diseases were excluded from COVID-19 vaccine trials. We therefore aimed to evaluate humoral and cellular immune responses to COVID-19 vaccine BNT162b2 (Pfizer-BioNTech) in patients taking methotrexate and commonl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahil, Satveer K, Bechman, Katie, Raharja, Antony, Domingo-Vila, Clara, Baudry, David, Brown, Matthew A, Cope, Andrew P, Dasandi, Tejus, Graham, Carl, Lechmere, Thomas, Malim, Michael H, Meynell, Freya, Pollock, Emily, Seow, Jeffery, Sychowska, Kamila, Barker, Jonathan N, Norton, Sam, Galloway, James B, Doores, Katie J, Tree, Timothy I M, Smith, Catherine H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266273/ https://www.ncbi.nlm.nih.gov/pubmed/34258590 http://dx.doi.org/10.1016/S2665-9913(21)00212-5

Ejemplares similares

Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
por: Mahil, Satveer K, et al.
Publicado: (2021)

055 The impact of methotrexate and targeted immunosuppression on cellular and humoral immune responses to COVID-19 vaccine BNT162b2: a cohort study
por: Mahil, S.K., et al.
Publicado: (2021)

Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
por: McKenzie, Duncan R., et al.
Publicado: (2021)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022)

BNT162b2 COVID-19 and ChAdOx1 nCoV-19 vaccination in patients with myelodysplastic syndromes
por: Abdul-Jawad, Sultan, et al.
Publicado: (2022)

Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
por: Harrington, Patrick, et al.
Publicado: (2021)

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
por: Harrington, Patrick, et al.
Publicado: (2021)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review
por: Liew, Su-Yi, et al.
Publicado: (2022)

A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis
por: Bechman, Katie, et al.
Publicado: (2020)

Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
por: Lechmere, Thomas, et al.
Publicado: (2022)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Development of antidrug antibodies against adalimumab maps to variation within the HLA-DR peptide-binding groove
por: Tsakok, Teresa, et al.
Publicado: (2023)

Concordance of B‐ and T‐cell responses to SARS‐CoV‐2 infection, irrespective of symptoms suggestive of COVID‐19
por: Österdahl, Marc F., et al.
Publicado: (2022)

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
por: Monin, Leticia, et al.
Publicado: (2021)

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
por: Seow, Jeffrey, et al.
Publicado: (2023)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
por: Haberman, Rebecca H, et al.
Publicado: (2021)

The immunosuppressed traveler: infection risks with autoimmunity and immunosuppression, vaccinations, and general travel advice
por: Allen, Victoria, et al.
Publicado: (2020)

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
por: Priddy, Frances H., et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data
por: Dey, Mrinalini, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
por: Seow, Jeffrey, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Update on psoriasis immunopathogenesis and targeted immunotherapy
por: Mahil, Satveer K., et al.
Publicado: (2015)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

The infection risks of JAK inhibition
por: Adas, Maryam A., et al.
Publicado: (2021)

BNT-162b1: Stevens-Johnson syndrome: case report
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Acute interstitial nephritis after vaccination with BNT162b2
por: Rieckmann, Sonja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j7gb80c12115j41jtpiatnh7cr